Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC

Journal of Intensive Care

Haruhiko Ogawa¹  Hidesaku Asakura² 

[1] Department of Environmental and Preventive Medicine, Kanazawa University, Takaramachi 13-1, 920-8640, Kanazawa, Ishikawa, Japan;Department of Hematology, Kanazawa University Hospital, Takaramachi 13-1, 920-8640, Kanazawa, Ishikawa, Japan;

关键词: COVID-19;    Thrombosis;    Fibrinolytic therapy;   

DOI  :  10.1186/s40560-020-00491-y

来源: Springer

【 摘 要 】

A high rate of thrombotic complications, such as pulmonary embolism, has been linked to mortality in COVID-19, and appropriate treatment of thrombosis is important for lifesaving. Although heparin is frequently used to treat thrombotic pathology in COVID-19, pulmonary embolism is still seen in severe cases. Although systemic fibrinolytic therapy is a focus of attention because a thrombotic pathology is the cause of death in severe COVID-19, it should be kept in mind that fibrinolytic therapy might be harmful at advanced stage of COVID-19 where the status of disseminated intravascular coagulation (DIC) has been transmitted from suppressed-fibrinolytic to enhanced-fibrinolytic in disease progression of COVID-19. In this respect, inhalation therapy with fibrinolytic substances might be a safe and promising treatment.

【 授权许可】

CC BY